- Rohto Pharma’s second quarter operating income was 6.00 billion yen, a significant decrease of 38% from the previous year, missing the estimated 11.08 billion yen.
- Net income for the same period fell by 41% year-over-year to 4.44 billion yen, below the anticipated 8.31 billion yen.
- Net sales increased by 6% year-over-year, reaching 70.73 billion yen, slightly under the expected 71.02 billion yen.
- Rohto Pharma maintains its full-year forecast with an operating income of 43.20 billion yen, against an estimate of 45.27 billion yen.
- The company forecasts a net income of 32.20 billion yen for the year, slightly below the expected 33.87 billion yen.
- For the year, expected net sales are set at 320.00 billion yen, close to the estimated 320.71 billion yen.
- Rohto Pharma plans to maintain its dividend at 33.00 yen per share, slightly above the estimate of 32.89 yen.
- The company’s stock receives strong support with 10 buy ratings and no hold or sell ratings.
A look at Rohto Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Rohto Pharmaceutical, a company engaged in manufacturing pharmaceuticals and cosmetics products, appears to have a promising long-term outlook based on the Smartkarma Smart Scores. With above-average scores in Growth and Momentum, Rohto Pharmaceutical is positioned for substantial growth and has strong market momentum. Additionally, the company demonstrates resilience, indicating its ability to withstand challenging market conditions. While the Value and Dividend scores are average, the overall outlook for Rohto Pharmaceutical suggests a positive trajectory in the long run.
Specializing in products like eyewash, bath soaps, gastrointestinal medicine, and hand cream, Rohto Pharmaceutical also diversifies its portfolio by manufacturing contact lenses and health foods. Through a license agreement with its subsidiary, Mentholatum (US), the company expands its reach by selling their brand products. This comprehensive product range and strategic partnerships are likely to contribute to Rohto Pharmaceutical‘s growth and success in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
